Hyperion Pharma Consultancy

The Netherlands

Helvoirtseweg 6
5261 CE Vught

P: +31 (0) 641221798 
E: info@hyperion-consultancy.nl
W: www.hyperion-consultancy.nl

Projects of Hyperion Pharma Consultancy

Food company, Belgium:
New application of existing product. Advise concerning GMP compliance and certification.

Food company, the Netherlands:
Manufacturer of food and feed ingredients:
Preparation and execution for a supplier audit (21CFR 210/211: GMP) on behalf of a pharmaceutical company.

Raw material manufacturer, the Netherlands:
Manufacturer of Active Pharmaceutical Ingredients (API's), vitamins and Cholesterol:
Preparation and execution for a supplier audit (IPEC GMP for excipients) on behalf of a pharmaceutical company.

Storage and Distribution company, the Netherlands:
Preparation and execution for a supplier audit (Eudralex – Volume 4: GMP and GDP) on behalf of a pharmaceutical company.

Wholesaler of veterinary medicinal products, the Netherlands and Belgium:
Preparation and execution for a supplier audit (EU GDP and Eudralex – Volume 4: GMP) on behalf of a pharmaceutical company.

Medical Device manufacturer (MDD), Belgium:
Preparation and execution for a supplier audit (ISO 13485:2003) on behalf of a pharmaceutical company.

Biopharmaceutical company, the Netherlands:
Quality Assurance support e.g GMP - and Internal Audit training.

Food company, the Netherlands:
Quality Assurance support and preparation for re-inspection GMP certificate.

API manufacturer, China:
Audit to verify the product has been manufactured according to GMP and is suitable for use in clinical trials.

Food company, The Netherlands:
Acting as Quality Manager at a Production Department Milk Protein, perform audits, continuous improvement of processes and other Quality Assurance issues.

Hyperion Pharma Consultancy uses cookies to analyze the use of the website. For example, through such statistics, it is examined how often you visit the website of Hyperion Pharma Consultancy. These cookies could also be placed by third parties. By accepting this announcement or continuing to use this site, you agree to this. More information